Development of compounds for the treatment of drug-resistant epilepsies

Based on a lead structure discovered in previous research a new class of drugs for the treatment of drug-resistant epilepsies will be developed. Depending on biological evaluation results, the lead structure will be altered and equipped with different substituents in order to enhance its anticonvulsive properties. Numerous techniques will be combined to provide sufficient diversity to the lead structure so that an extensive structure-activity relationship (SAR) can be acquired. All compounds will be biologically evaluated using a zebrafish larvae seizure model, while the most promising ones will be submitted to an acute and chronic 6 Hz mouse model as well. Identification of the molecular target will be performed using affinity chromatography and chemical yeast-3-hybrid-profiling (CY3H).

Jaar van publicatie:2022

Toegankelijkheid:Closed